Novartis links up with Mayo Clinic spinout Anumana to develop ECG-reading AI
Related Articles
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosisJune 21, 2023
Anumana Advances AI-Driven Cardiovascular Science with Late-Breaking Heart Failure Study and Multiple Abstracts at AHA 2025
Simultaneous publication in Journal of the American College of Cardiology demonstrates impact of ECG-AI on heart failure risk assessment. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in AI-powered cardiovascular diagnostics, today announced…November 20, 2025
Anumana Appoints Maulik Nanavaty as CEO
Anumana Appoints Maulik Nanavaty as CEOCAMBRIDGE, Mass. – October 19, 2023 – Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, today announced that Maulik Nanavaty…October 19, 2023
Anumana wins FDA clearance for ECG-AI algorithm
Mass Device: Anumana announced that it received FDA 510(k) clearance for its AI-powered ECG-AI LEF medical device.October 03, 2023